LOS ANGELES, Aug. 19, 2019 /PRNewswire-PRWeb/ -- Apex Biosciences and Slyngshot Health have announced the completion of a merger of all infrastructure to form The Anthos Group. The newly formed company owns various assets and intellectual property that is poised to disrupt the hemp and cannabinoid industry.
Apex Biosciences operation facilities are in Eugene, OR and they specialize in agricultural science and hemp cultivation. Through the development of novel agricultural programs, Apex Biosciences has passed numerous inspections by regulatory bodies to assure the compliance of their products and practices. As a result, Apex Biosciences became a desirable partner for Slyngshot Health, based out of Chicago, IL, which was a medically focused company that specialized in technology, education, and Personalized Medicine. As the company grew, their large network of healthcare providers requested more education around cannabinoids, particularly cannabidiol (CBD).
"As we researched the CBD industry to bring education to our healthcare partners, we realized that many products were not of high quality and were actually dangerous due to different contaminants. This provided an opportunity to bring a high purity product to market that our healthcare providers could comfortably recommend for their patients," said Badal Shah, CEO of The Anthos Group.
"It is an exciting time to be in the CBD industry, and this merger positions The Anthos Group to be a leader in agriculture, compliance, quality organic products, and medical application," said Shah.
Shan Umer, President of The Anthos Group, explained that the only way to truly guarantee quality of a final product is to control every step in its production, the true definition of seed to shelf. "Based on what we had seen in the industry, we knew that we could make a superior product by simply focusing on the pure science of cultivation. Our farms employ organic practices and nurture products that are non-GMO, pesticide-free, and are consistently high in CBD yield through our hemp cloning programs," said Umer.
Natural, organic products are a priority for The Anthos Group, whom also employs physicians and pharmacists of various therapeutic areas to assure products are safe and effective for customers. This enables the company to launch product lines in the cosmetic, medical, lifestyle, and fitness segments, reaching a wide span of customers that may find benefits in these natural product lines.
"In treating patients with acute and chronic pain issues, my options have been limited. If patients require ongoing medications for management, typically the risks outweigh any perceived benefits up until now. With the advent of medical quality CBD products, we finally have something with very low risk/very high reward, and an incredibly high level of compliance and patient satisfaction. I foresee the role of CBD products to only increase in the practice of safe and quality medicine," said Akash Bajaj, MD, MPH - Medical Director at Remedy Pain Solutions.
The cannabinoid/CBD market is projected to be upwards of $20 Billion over the next five years, and The Anthos Group is amid Series A funding to support their growth within the industry. The Anthos Group is headquartered in Los Angeles, CA and sports an impressive portfolio of consumer brands and private label partners.
For more information, please visit: http://www.theanthos.com
About
Apex Biosciences and Slyngshot Health have merged to form The Anthos Group, offering a unique seed to shelf transparency injected with agricultural expertise and clinical guidance. The company is focused on cultivating and bringing organic, high-quality hemp products to market through the launch of three dynamic brands, all originating from Anthos Group facilities in Oregon.
Media Contact
Company Name: The Anthos Group
Contact Person: Cohin Kakar, CMO
Email: media@theanthos.com
Phone: (888) 424-0029
City: Los Angeles
State: CA
Country: United States
Website: http://www.theanthos.com
SOURCE The Anthos Group
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
